Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

SGT-501

Other · developed by Solid Biosciences

Phase 1 Most advanced trial
SLDB Developer
1 Registered trials

What is SGT-501?

SGT-501 is an investigational drug studied in Catecholaminergic Polymorphic Ventricular Tachycardia.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
Solid Biosciences Inc. (SLDB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07148089 Phase 1 Catecholaminergic Polymorphic Ventricular Tachycardia Recruiting SLDB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Catecholaminergic Polymorphic Ventricular Tachycardia

More from Solid Biosciences

SGT-003 Phase 3 SGT-212 Phase 1

Follow SLDB, the company behind SGT-501

See SLDB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLDB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.